JP2010509234A - 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 - Google Patents

新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 Download PDF

Info

Publication number
JP2010509234A
JP2010509234A JP2009535486A JP2009535486A JP2010509234A JP 2010509234 A JP2010509234 A JP 2010509234A JP 2009535486 A JP2009535486 A JP 2009535486A JP 2009535486 A JP2009535486 A JP 2009535486A JP 2010509234 A JP2010509234 A JP 2010509234A
Authority
JP
Japan
Prior art keywords
antibody
patient
cells
leukemia
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009535486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509234A5 (https=
Inventor
ジョナサン ジー． ドラックマン，
メイ キュング サザーランド，
エリック ジーバース，
グラント リスドン，
エゾゲリン オフラゾグリュ，
アラン ワール，
ティム ルイス，
Original Assignee
シアトル ジェネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル ジェネティックス， インコーポレイテッド filed Critical シアトル ジェネティックス， インコーポレイテッド
Publication of JP2010509234A publication Critical patent/JP2010509234A/ja
Publication of JP2010509234A5 publication Critical patent/JP2010509234A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2009535486A 2006-11-02 2007-11-02 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 Pending JP2010509234A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85653006P 2006-11-02 2006-11-02
US87443906P 2006-12-11 2006-12-11
US94302107P 2007-06-08 2007-06-08
PCT/US2007/083508 WO2008058021A2 (en) 2006-11-02 2007-11-02 Methods of treating neoplastic, autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2010509234A true JP2010509234A (ja) 2010-03-25
JP2010509234A5 JP2010509234A5 (https=) 2010-12-16

Family

ID=39365271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535486A Pending JP2010509234A (ja) 2006-11-02 2007-11-02 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法

Country Status (6)

Country Link
US (3) US20110038856A1 (https=)
EP (1) EP2084527A4 (https=)
JP (1) JP2010509234A (https=)
AU (1) AU2007317333A1 (https=)
CA (1) CA2667808A1 (https=)
WO (1) WO2008058021A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794266A (zh) * 2014-07-01 2017-05-31 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
JP2018533909A (ja) * 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
US10738118B2 (en) 2015-05-29 2020-08-11 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
AU2007317333A1 (en) 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es) 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
HUE032563T2 (en) 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
CA2722184A1 (en) 2008-04-25 2009-10-29 Duke University Regulatory b cells and their uses
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
WO2011022861A1 (zh) * 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 氟维司群纳米球/微球及其制备方法和用途
CA2773579C (en) 2009-09-10 2019-01-15 Kyowa Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066374A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
EP2600878A4 (en) 2010-08-04 2014-06-11 Univ Duke REGULATORY B-CELLS AND ITS USES
UA112062C2 (uk) * 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
HK1212448A1 (en) 2012-09-07 2016-06-10 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
AU2013323472B2 (en) 2012-09-28 2018-07-05 Ellis KLINE Glycosidase regimen for treatment of infectious disease
AU2014207429B2 (en) * 2013-01-18 2018-11-01 Ellis KLINE Selective glycosidase regimen for immune programming and treatment of cancer
WO2014159923A1 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Enhancement of vaccines
AR097648A1 (es) * 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
GB201319620D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
WO2015085171A1 (en) * 2013-12-06 2015-06-11 Adventist Health Systems/Sunbelt, Inc. Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
JOP20170091B1 (ar) * 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
WO2018112407A1 (en) 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
US20230132400A9 (en) * 2017-11-10 2023-04-27 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
MX2021002299A (es) 2018-08-31 2021-04-28 Alector Llc Anticuerpos de anti-cd33 y metodos para usarlos.
EP3863644A4 (en) * 2018-10-12 2022-10-05 Jeanmarie Guenot CD33×CD3-BINDING PROTEINS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND DISEASES
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
US20220331247A1 (en) * 2019-09-23 2022-10-20 Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec Polymeric micelle, methods of production and uses thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2022075756A1 (ko) * 2020-10-08 2022-04-14 주식회사 큐롬바이오사이언스 베타-라파촌을 유효성분으로 포함하는 담즙 정체성 간질환 예방 또는 치료용 약학 조성물
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502888A (ja) * 1996-08-09 2001-03-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Ｃｄ３３様タンパク質をコードするヌクレオチド配列
JP2004505994A (ja) * 2000-08-08 2004-02-26 イムノメディクス，　インコーポレイテッド 慢性骨髄性白血病の免疫療法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991009058A1 (en) * 1989-12-14 1991-06-27 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
US6007814A (en) * 1992-06-15 1999-12-28 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US7194554B1 (en) * 1998-12-08 2007-03-20 Nomadix, Inc. Systems and methods for providing dynamic network authorization authentication and accounting
AU2002348178A1 (en) * 2002-11-06 2004-06-03 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
BR0316101A (pt) * 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
AU2005306325A1 (en) * 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of HIF-1 mediated disorders with adenosine A3 receptor agonists
WO2006063150A2 (en) * 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
AU2007317333A1 (en) 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502888A (ja) * 1996-08-09 2001-03-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Ｃｄ３３様タンパク質をコードするヌクレオチド配列
JP2004505994A (ja) * 2000-08-08 2004-02-26 イムノメディクス，　インコーポレイテッド 慢性骨髄性白血病の免疫療法

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794266A (zh) * 2014-07-01 2017-05-31 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
JP2017521415A (ja) * 2014-07-01 2017-08-03 アンフィヴェナ セラピューティクス，インク． 二重特異性ｃｄ３３およびｃｄ３結合タンパク質
US10626190B2 (en) 2014-07-01 2020-04-21 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN106794266B (zh) * 2014-07-01 2021-02-23 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
CN112851820A (zh) * 2014-07-01 2021-05-28 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
JP2022068346A (ja) * 2014-07-01 2022-05-09 アンフィヴェナ セラピューティクス，インク． 二重特異性ｃｄ３３およびｃｄ３結合タンパク質
CN112851820B (zh) * 2014-07-01 2023-11-28 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白
US10738118B2 (en) 2015-05-29 2020-08-11 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
US11753469B2 (en) 2015-05-29 2023-09-12 Anji Bruno, Llc Methods of using bispecific CD33 and CD3 binding proteins
JP2018533909A (ja) * 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
JP2021178831A (ja) * 2015-08-28 2021-11-18 アムニクス ファーマシューティカルズ， インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法
JP2024105275A (ja) * 2015-08-28 2024-08-06 アムニクス ファーマシューティカルズ， インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法

Also Published As

Publication number Publication date
WO2008058021A2 (en) 2008-05-15
CA2667808A1 (en) 2008-05-15
AU2007317333A1 (en) 2008-05-15
US20100215653A1 (en) 2010-08-26
US7695716B2 (en) 2010-04-13
EP2084527A4 (en) 2011-07-27
EP2084527A2 (en) 2009-08-05
US20080267960A1 (en) 2008-10-30
US20110038856A1 (en) 2011-02-17
WO2008058021A3 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
JP2010509234A (ja) 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
JP4303964B2 (ja) 組換え抗ｃｄ３０抗体およびその使用
JP2022137076A (ja) 抗ｃｄ３３抗体及びその使用方法
KR102663440B1 (ko) 인간화된 항-ccr7 리셉터 항체
JP2020517302A (ja) Ｃｄ１９に対するヒト化抗原結合ドメイン及び使用方法
KR20100094527A (ko) 백혈병 줄기세포의 억제 방법
KR20180054639A (ko) 항-siglec-7 항체 및 이의 사용 방법
KR20090088877A (ko) 항-ｃｄ20 항체 및 이용 방법
RS20050467A (sr) Varijante imunoglobulina i njihova upotreba
JP2022538733A (ja) 新規抗ｃｄ２５抗体
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
KR20230093010A (ko) 신규 항-lilrb2 항체 및 유도체 생성물
TW202116807A (zh) 用於治療特定患者之癌症的抗體組合
JP2023533793A (ja) 治療用抗体およびそれらの使用
TWI857982B (zh) 特異性結合至ｃｄ２０的單株抗體
JP2023523890A (ja) Ｈｓｐ７０を標的とするモノクローナル抗体およびその治療的使用
US20210032360A1 (en) Antibodies against bst1 for preventing or treating myelodysplastic syndrome
WO2022192423A1 (en) Anti-human cxcr5 antibody and uses thereof
WO2025026333A1 (en) Antibody against fgfr2b, method for preparing the same, and use thereof
BR112020001320A2 (pt) combinações farmacêuticas que compreendem um anticorpo anti-bst-1 e um análogo de citidina
WO2025179282A1 (en) Antibodies targeting epstein-barr virus proteins and methods of use
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120927

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130313